Micro
Emerging
Active
MDCXW FDA 进展和临床展望扩展
新的叙述，覆盖范围有限 — 仍在形成中。
评分
0.5
动能
▲ 0.0
文章
1
来源
1
情绪时间线
事件时间线
假设
Pending
到期: 2026年7月18日
MDCXW trading volume will increase by at least 40% average daily volume in the 30 days following FDA progress announcement compared to 30-day pre-announcement baseline
Pending
到期: 2026年11月15日
MDCXW will complete enrollment for at least one Phase 2 or Phase 3 clinical trial by end of Q2 2026, as evidenced by regulatory filings or company announcements
Pending
到期: 2026年8月17日
MDCXW stock price will appreciate by at least 15% within 90 days following positive FDA feedback on clinical trial progression announced in Q1 2026
时间线
最后更新五月 19, 2026